Oxaliplatin in Treating Children With Recurrent or Refractory Medulloblastoma, Supratentorial Primitive Neuroectodermal Tumor, or Atypical Teratoid Rhabdoid Tumor

You may be eligible if

• DISEASE CHARACTERISTICS:
• Histologically confirmed medulloblastoma, supratentorial primitive neuroectodermal tumor (including pineoblastomas and ependymoblastomas), or atypical teratoid rhabdoid tumor
• * Recurrent or refractory disease
• Measurable disease by radiography
• Patients with positive cerebrospinal fluid cytology or linear leptomeningeal disease are eligible
• PATIENT CHARACTERISTICS:
• Age
• 21 and under
• Performance status
• Karnofsky 50-100% OR
• Lansky 50-100%
• Life expectancy
• Not specified
• Hematopoietic
• Absolute neutrophil count at least 1,000/mm\^3
• Platelet count at least 100,000/mm\^3 (transfusion independent)
• Hemoglobin at least 8.0 g/dL (RBC transfusions allowed)
• Hepatic
• Bilirubin no greater than 1.5 times normal
• ALT less than 2.5 times normal
• Renal
• Creatinine no greater than 1.5 times normal OR
• Creatinine clearance or radioisotope glomerular filtration rate at least 70 mL/min
• Cardiovascular
• Shortening fraction at least 27% by echocardiogram OR
• Ejection fraction at least 50% by MUGA
• Pulmonary
• No dyspnea at rest
• No exercise intolerance
• Pulse oximetry greater than 94%
• Other
• No uncontrolled infection
• No active graft-versus-host disease
• No uncontrolled seizure disorders
• * Seizure disorders well controlled with anticonvulsants allowed
• Not pregnant or nursing
• Negative pregnancy test
• Fertile patients must use effective contraception
• PRIOR CONCURRENT THERAPY:
• Biologic therapy
• At least 2 weeks since prior growth factors
• At least 6 months since prior allogeneic stem cell transplantation
• No concurrent colony-stimulating factors during the first course of study
• No concurrent immunomodulating agents
• Chemotherapy
• At least 3 weeks since prior myelosuppressive therapy (6 weeks for nitrosoureas) and recovered
• No other concurrent anticancer chemotherapy
• Endocrine therapy
• If concurrent corticosteroids necessary for intracranial pressure, must be on stable or decreasing dose for at least 1 week prior to study
• No other concurrent corticosteroids
• Radiotherapy
• At least 2 weeks since prior local palliative radiotherapy (small port) to symptomatic metastatic sites
• At least 3 months since prior craniospinal radiotherapy
• No concurrent palliative radiotherapy
• Recovered from prior radiotherapy
• Surgery
• Not specified
• Other
• No other concurrent anticancer or experimental drugs